Moreover, a significant decrease in the percentage of melanotic melanoma cells in the S (16% for control vs. 2% for 200 μM of TGC) and G2/M phases (21% for control vs. 14% for 200 μM of TGC) was observed after the treatment. Here, TGM2 is linked to melanoma.